Shares of Glenmark Pharmaceuticals will be in the spotlight after the company received ANDA approval from the US FDA for its Olopatadine Hydrochloride Ophthalmic Solution. This product, used to treat allergic eye conditions, strengthens Glenmark’s ophthalmic portfolio in the US market.
Piramal Pharma is also in focus as its subsidiary secured market authorization from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for Neoatrico®, a ready-to-use Dopamine Hydrochloride infusion developed for neonatal and pediatric patients.
Ajanta Pharma announced a key expansion move, revealing plans to establish a new liquid formulation facility at its Pithampur site, which will help the company cater to both domestic and export markets.
Unichem Laboratories has successfully completed Phase I of its API plant expansion at Pithampur, increasing its capacity by 210 KL. The plant is now operating at 70% utilization, with the expansion expected to drive enhanced manufacturing efficiency.
Dr. Reddy’s Laboratories also made headlines as promoter Satish Reddy acquired a 0.67% stake (56,02,495 shares) via transmission from Late Mrs. Samrajyam Reddy, a development that reinforces promoter confidence in the company.
Disclaimer: This article is for informational purposes only and is not a recommendation to buy or sell any stock. Please consult a certified financial advisor before making investment decisions.
